Benign breast disease and the risk of XXXX in the next 15 years.

@entity1 @entity82 @entity0 @entity5 @entity75 @entity1373 @entity513 @entity2416 @entity1557
AIM: Fibrocystic mastosis (FCM) is defined by the totality of dystrophic changes of the mammary tissue, the grouping in the form of @entity82 of epithelial, cystic, metaplastic and hyperplastic alterations. A very good estimation of the @entity5 risk is related specifically to the microscopic aspect. Other factors, the family history as well as the presence of an inherited gene determining the increase in the risk of @entity0 are also considered. But, if a @entity1 known with @entity2416 has not undergone any biopsy, then it is impossible to calculate the specific individual risk of developing @entity5 . MATERIAL AND METHODS: The data collected as a study material and considered refer to: the total num- ber of cases investigated and diagnosed with @entity2416 , the annual distribution of this disease cases, the distribution of the cases according to age groups, admission reasons, clinical examination, personal pathologic history clinically significant for the basic disease (the main diagnosis), the family medical history significant for the basic disease, the anatomopathological diagnosis. RESULTS: Between 2004 and 2006, at "Cuza Vod  " Obstetrics and Gynecology Hospital of Ia  i, a maximum number of cases is noticed in 2006, when there were 147 cases, and the lowest number of cases was in 2005. There was high frequency of the anatomopathological examinations that highlighted the presence of @entity75 (both proliferative and non-proliferative), and the second most often diagnosis is @entity1557 . Though @entity2416 is not clearly defined, it is still admitted that in order to support this diagnosis it is first compulsory to exclude @entity5 . CONCLUSIONS: Only in 5% of the @entity1 with @entity2416 cellular changes can be revealed in the form of @entity1373 , which are a risk factor for @entity5 . The lesion that delimits @entity5 from non- @entity5 is @entity513 in situ. An incidence of over 20% is present in the countries that use mammographic screening programmes, mammographic surveillance programmes and programmes for the guided localization of nonpalpable lesions of the mammary gland.
